Skip to main content

Avycaz News

Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients

DUBLIN, March 18, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA)...

FDA Approves Avycaz (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

DUBLIN, Feb. 1, 2018 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan's...

FDA Medwatch Alert: Avycaz (ceftazidime and avibactam): Drug Safety Communication - Dose Confusion and Medication Errors

ISSUE: FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and avibactam) due to confusion about the drug strength...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Pneumonia, Kidney Infections, Urinary Tract Infection

Avycaz patient information at Drugs.com